Psychological resilience: the hidden key to managerial support and performance in teachers. [PDF]
Dursun M +4 more
europepmc +1 more source
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
Enterprise performance and talent innovation training in new enterprises based on social exchange theory and organizational psychology. [PDF]
Gao B, Zhang X.
europepmc +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Psychological pathways between leadership behavior and work-family balance: the mediating roles of employee satisfaction and perceived support. [PDF]
Wang P, Lyu B, Yang Q, Wan Q.
europepmc +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Effectiveness or efficiency: the impact of performance pressure and time pressure on employee feedback-seeking behavior. [PDF]
Lan M, Nie T.
europepmc +1 more source
Yohanes Sugiyanta, Vino Ilhami
doaj +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Explainable attrition risk scoring for managerial retention decisions in human resource analytics. [PDF]
Pavithran MS, Vadivel SM.
europepmc +1 more source

